SEC Form 4 · accession 0001140361-17-023988

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Sanofi

10% Owner

Period of report

Jun 2, 2017

Accepted (ET)

Jun 6, 2017 · 5:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000872589

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3,F4	Jun 2, 2017	P	402	$466.3828	A	23,506,096	I	See note
Common Stock^F1,F2,F5,F4	Jun 2, 2017	P	400	$468.10	A	23,506,496	I	See note
Common Stock^F1,F2,F6,F4	Jun 2, 2017	P	2,132	$469.8097	A	23,508,628	I	See note
Common Stock^F1,F2,F7,F4	Jun 2, 2017	P	13,544	$470.7248	A	23,522,172	I	See note
Common Stock^F1,F2,F8,F4	Jun 2, 2017	P	7,443	$471.8245	A	23,529,615	I	See note
Common Stock^F1,F2,F9,F4	Jun 2, 2017	P	5,806	$473.0711	A	23,535,421	I	See note
Common Stock^F1,F2,F10,F4	Jun 2, 2017	P	7,068	$473.8843	A	23,542,489	I	See note
Common Stock^F1,F2,F11,F4	Jun 2, 2017	P	12,020	$475.1593	A	23,554,509	I	See note
Common Stock^F1,F2,F12,F4	Jun 2, 2017	P	6,312	$476.1472	A	23,560,821	I	See note
Common Stock^F1,F2,F13,F4	Jun 2, 2017	P	6,507	$478.9431	A	23,567,328	I	See note
Common Stock^F1,F2,F14,F4	Jun 2, 2017	P	12,710	$480.1698	A	23,580,038	I	See note
Common Stock^F1,F2,F15,F4	Jun 2, 2017	P	15,197	$481.1292	A	23,595,235	I	See note
Common Stock^F1,F2,F16,F4	Jun 2, 2017	P	23,490	$482.0789	A	23,618,725	I	See note
Common Stock^F1,F2,F17,F4	Jun 2, 2017	P	18,311	$483.0403	A	23,637,036	I	See note
Common Stock^F1,F2,F18,F4	Jun 2, 2017	P	4,708	$484.0367	A	23,641,744	I	See note

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F10Purchase prices range from $473.45 to $474.10 per share, inclusive.
F11Purchase prices range from $474.50 to $475.49 per share, inclusive.
F12Purchase prices range from $475.70 to $476.47 per share, inclusive.
F13Purchase prices range from $478.53 to $479.48 per share, inclusive.
F14Purchase prices range from $479.54 to $480.51 per share, inclusive.
F15Purchase prices range from $480.54 to $481.53 per share, inclusive.
F16Purchase prices range from $481.57 to $482.56 per share, inclusive.
F17Purchase prices range from $482.57 to $483.50 per share, inclusive.
F18Purchase prices range from $483.57 to $484.50 per share, inclusive.
F2Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
F3Purchase prices range from $465.88 to $466.56 per share, inclusive.
F4Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
F5Purchase prices range from $468.01 to $468.29 per share, inclusive.
F6Purchase prices range from $469.19 to $470.04 per share, inclusive.
F7Purchase prices range from $470.31 to $470.99 per share, inclusive.
F8Purchase prices range from $471.43 to $472.25 per share, inclusive.
F9Purchase prices range from $472.45 to $473.33 per share, inclusive.

Remarks

Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.).